Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally?

• If you are wondering whether Jazz Pharmaceuticals at around US$194.20 is still offering value after a strong run, the key is to look closely at what the current price actually reflects.
• The stock has posted returns of 3.9% over the last 7 days, 8.8% over 30 days, 12.2% year to date, and 93.2% over the past year, which naturally raises questions about how much of the story is already priced in and how risk is being perceived.
• Recent attention on Jazz Pharmaceuticals has centered on its position within the wider pharmaceuticals and biotech space and how investors are reassessing companies with established product portfolios and pipelines. This broader interest helps frame the recent share price moves as part of a wider reassessment of where value may sit in the sector.
• Jazz Pharmaceuticals currently has a valuation score of 5 out of 6. The next step is to break down what different valuation approaches suggest about this stock and then look at an even more comprehensive way to think about value at the end of the article.

Jazz Pharmaceuticals delivered 93.2% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Jazz Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and discounting them back to a present value. It is essentially asking what tomorrow’s cash is worth in today’s dollars.

For Jazz Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $1.25b. Analyst estimates and subsequent extrapolations in the source model set annual free cash flow figures between roughly $1.56b and $2.66b over the next decade, with a specific projection of $2.12b in 2030. Simply Wall St uses analyst inputs for the earlier years, then extends the trend further out within its methodology.

Using those projected cash flows and discounting them back to today results in an estimated intrinsic value of about $776.61 per share in that model. Compared with the current share price around $194.20, this framework indicates the stock is about 75.0% below this intrinsic estimate, which highlights a substantial difference between the model’s valuation output and the market price on this measure.

Result: UNDERVALUED (based on the DCF model described)

Our Discounted Cash Flow (DCF) analysis suggests Jazz Pharmaceuticals is undervalued by 75.0%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Jazz Pharmaceuticals.

Approach 2: Jazz Pharmaceuticals Price vs Sales

P/S is a common way to look at valuation for profitable healthcare companies, because it links what you pay directly to the revenue the business is generating, without getting caught up in short term swings in earnings. What counts as a “normal” or “fair” P/S usually reflects how much growth investors expect and how much risk they see in those future sales.

Jazz Pharmaceuticals currently trades on a P/S of 2.80x. That sits below the Pharmaceuticals industry average of 4.59x and also below the peer group average of 3.56x. This suggests the market is assigning a lower price tag to each dollar of Jazz’s revenue than to many comparable names.

Simply Wall St’s Fair Ratio for Jazz Pharmaceuticals is 7.25x. This is its estimate of an appropriate P/S once factors like earnings growth, profit margins, industry, market cap and company specific risks are taken into account. Because this Fair Ratio is materially higher than the current 2.80x P/S, this approach points to Jazz Pharmaceuticals trading at a discount on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Jazz Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as simple stories that you create about Jazz Pharmaceuticals. These link your view on its products, risks and opportunities to specific revenue, earnings and margin forecasts. Those then roll up into a Fair Value, which you can compare to the current price to judge whether the stock looks expensive or cheap to you.

On Simply Wall St’s Community page, Narratives are available as an easy tool used by millions of investors. They update automatically when fresh news, guidance or earnings arrive, so your Fair Value view does not sit frozen while the information changes.

For Jazz Pharmaceuticals, one investor might build a more cautious Narrative around a Fair Value of about US$188, focusing on patent expiries, generic competition and pricing pressure. Another might lean into a Fair Value closer to US$264, emphasizing CNS durability and the potential of oncology assets like Ziihera and zanidatamab. It is this spread of credible stories that helps you decide which view you think is more realistic before you act.

For Jazz Pharmaceuticals however we will make it really easy for you with previews of two leading Jazz Pharmaceuticals Narratives:

🐂 Jazz Pharmaceuticals Bull Case

Fair Value in this narrative: US$219.40

Price vs Fair Value: around 11.5% below this Fair Value based on the last close of US$194.20

Revenue growth assumption: 7.85%

• Sees HER2 assets like Ziihera and zanidatamab and the broader oncology and neuroscience portfolio as key drivers for future earnings power and portfolio expansion across multiple indications and geographies.
• Builds on expectations for higher revenue, a move to an 18.4% profit margin and a future P/E of about 17x, with a Fair Value of US$219.40 and an analyst consensus target around US$186.47.
• Flags meaningful risks around patent expiries, generic and branded competition, drug pricing pressure, reliance on a handful of product launches and a sizeable debt load that could weigh on flexibility.

🐻 Jazz Pharmaceuticals Bear Case

Fair Value in this narrative: US$188.00

Price vs Fair Value: around 3.3% above this Fair Value based on the last close of US$194.20

Revenue growth assumption: 3.02%

• Frames Jazz as more exposed to patent expirations, generics, pricing pressure and acquisition risk, especially in sleep and rare disease, which could limit long term earnings growth.
• Uses more cautious assumptions, with revenue growing at about 3.0% a year, margins rising to 22.1% and a future P/E of about 13.8x to arrive at a Fair Value of US$188.00, close to the more bearish analyst targets.
• Highlights that oncology and pipeline execution, regulatory outcomes and how oxybate competition plays out are central swing factors that could challenge this more conservative view.

If you want to see how these Jazz Pharmaceuticals Narratives look in full, including detailed assumptions and forecast paths, you can review both and then decide which story feels closer to your own expectations for the business. See what the community is saying about Jazz Pharmaceuticals

Do you think there’s more to the story for Jazz Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com